Talbot JN - Search Results

1

[18F]-FDG positron imaging in clinical management of lymphoma patients.

Talbot JN, Haioun C, Rain JD, Meignan M, Wioland M, Misset JL, Grahek D, Kerrou K, Montravers F. Talbot JN, et al. Crit Rev Oncol Hematol. 2001 Jun;38(3):193-221. doi: 10.1016/s1040-8428(01)00127-5. Crit Rev Oncol Hematol. 2001. PMID: 11369254 Review.

2

Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia.

Montravers F, Coutris G, Sarda L, Mensch B, Talbot JN. Montravers F, et al. Among authors: talbot jn. Eur J Nucl Med. 1993 Nov;20(11):1070-7. doi: 10.1007/BF00173485. Eur J Nucl Med. 1993. PMID: 8287875

3

Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.

Montravers F, Younsi N, Rousseau C, Philippe C, Seddiki M, Uzan S, Izrael V, Talbot JN. Montravers F, et al. Among authors: talbot jn. Anticancer Res. 1997 May-Jun;17(3B):1683-6. Anticancer Res. 1997. PMID: 9179218

4

Reevaluaton of the usefulness of systematic bone scanning in initial staging and follow-up of small cell lung carcinoma, taking into account the serum levels of neuron-specific enolase.

Gendreau V, Montravers F, Philippe C, Talbot JN. Gendreau V, et al. Among authors: talbot jn. Int J Biol Markers. 1997 Oct-Dec;12(4):148-53. doi: 10.1177/172460089701200402. Int J Biol Markers. 1997. PMID: 9582603 Review.

5

CA 15-3 and bone scintigraphy in the follow-up of breast cancer.

Younsi N, Montravers F, Philippe C, Seddiki M, Uzan S, Izrael V, Talbot JN. Younsi N, et al. Among authors: talbot jn. Int J Biol Markers. 1997 Oct-Dec;12(4):154-7. doi: 10.1177/172460089701200403. Int J Biol Markers. 1997. PMID: 9582604 Review.

6

[Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].

Maublant J, Vuillez JP, Talbot JN, Lumbroso J, Muratet JP, Herry JY, Artus JC. Maublant J, et al. Among authors: talbot jn. Bull Cancer. 1998 Nov;85(11):935-50. Bull Cancer. 1998. PMID: 9951421 Free article. French.

7

In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma.

Montravers F, Rousseau C, Doublet JD, Gattengo B, Allard S, Fouret P, Bernaudin JF, Thibault P, Talbot JN. Montravers F, et al. Among authors: talbot jn. Nucl Med Commun. 1998 Oct;19(10):953-61. doi: 10.1097/00006231-199810000-00005. Nucl Med Commun. 1998. PMID: 10234675

8

Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera.

Montravers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B, Rossert J, Costa de Beauregard MA, Thibault P, Talbot JN. Montravers F, et al. Among authors: talbot jn. J Nucl Med. 2000 Jan;41(1):78-84. J Nucl Med. 2000. PMID: 10647608 Free article.

9

Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin.

Périé S, Talbot JN, Monceaux G, Grahek D, Kerrou K, Montravers F, St Guily JL. Périé S, et al. Among authors: talbot jn. Ann Otol Rhinol Laryngol. 2000 Aug;109(8 Pt 1):755-60. doi: 10.1177/000348940010900810. Ann Otol Rhinol Laryngol. 2000. PMID: 10961809 Clinical Trial.

10

Myocardial viability assessment with FDG imaging: comparison of PET, SPECT, and gamma-camera coincidence detection.

Kerrou K, Toussaint JF, Froissart M, Talbot JN. Kerrou K, et al. Among authors: talbot jn. J Nucl Med. 2000 Dec;41(12):2099. J Nucl Med. 2000. PMID: 11138698 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters